Buy this biotech stock on pivot to immune disease treatments, Wells Fargo says
The bank's research arm raised its rating on the stock to overweight from equal weight.
ORIGINAL SOURCE →via CNBC Top News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] Can we stop demonizing each other over the West Bank - opinion
- [FINANCE] Edge Hound brings institutional-grade market intelligence to retail invvestors
- [FINANCE] IDF officers charged with embezzling millions, laundering funds via crypto
- [FINANCE] Five times President Trump made a statement that moved bitcoin, and why it might happen again this week
- [FINANCE] Polymarket in Talks to Raise $400M at $15B Valuation: Report
- [FINANCE] Bitcoin faces near-term pressure as liquidity tightens, Hilbert Group CIO says